Fibrinolytic Agents (Antithrombotic Agents)

Subscribe to Selected New Research on Fibrinolytic Agents

1650 relevant articles (154 outcomes, 235 trials/studies) found for this Bio-Agent

Description: Fibrinolysin or agents that convert plasminogen to fibrinolysin (PLASMIN).

Also Known As:

Antithrombotic Agents; Antithrombic Drugs; Fibrinolytic Drugs; Thrombolytic Drugs; Thrombolytic Agents

Relationship Network

Bio-Agent Context: Research Results

Chemical Actions and Uses

Pharmacologic Actions: 49

Therapeutic Uses: 203

Cardiovascular Agents: 241

Fibrinolytic Agents: 1650

Hematologic Agents: 1

Fibrinolytic Agents: 1650

Molecular Mechanisms of Pharmacological Action: 5

Fibrin Modulating Agents

Fibrinolytic Agents: 1650

Experts

1.	Mukherjee, Debabrata: 2 articles (04/2008 - 12/2004)
2.	Gibson, C Michael: 2 articles (10/2006 - 06/2006)
3.	Jennings, Lisa K: 2 articles (10/2006 - 06/2006)
4.	Cohen, David J: 2 articles (10/2006 - 06/2006)
5.	Braunwald, Eugene: 2 articles (10/2006 - 06/2006)
6.	McCabe, Carolyn H: 2 articles (10/2006 - 06/2006)
7.	Palabrica, Theresa M: 2 articles (10/2006 - 06/2006)
8.	TIMI Study Group: 2 articles (10/2006 - 06/2006)
9.	Murphy, Sabina A: 2 articles (10/2006 - 06/2006)
10.	Stone, Peter H: 2 articles (10/2006 - 06/2006)

Related Diseases

1.	Myocardial Infarction 07/05/2005 - "Recent studies have indicated that a selective inhibitor of TAFIa could enhance the efficacy of existing thrombolytic agents for the treatment of acute myocardial infarction, one of the most prevalent forms of heart attacks. " 01/01/2004 - "This review examines the most significant trends in the pharmacologic therapy of ST-segment elevation myocardial infarction since the publication of these early studies: the development of fibrinolytic drugs with improved clot selectivity and improved pharmacokinetic profiles that simplify administration, making ED or even prehospital thrombolysis more practical. " 01/01/1984 - "The development of newer specific thrombolytic agents with low toxicity, without antigenicity, and available for rapid parenteral administration holds much promise for the treatment of acute myocardial infarction in the future." 10/01/2004 - "BACKGROUND: Patients in clinical trials of fibrinolytic agents have been shown to be younger, less often female, and to have lower risk characteristics and a better outcome compared with unselected patients with ST-elevation myocardial infarction. " 03/01/1997 - "Early and sustained flow of grade 3 according to Thrombolysis in Myocardial infarction (TIMI) criteria and reocclusion rates are the key measures that define the physiologic efficacy of thrombolytic agents in the treatment of acute myocardial infarction. " Order ALL the reference details at left...
2.	Thrombosis (Thrombus) 01/01/2002 - "Thrombolytic agents have been successfully employed in each of these areas, achieving dissolution of the occluding thrombus, reconstitution of blood flow, and improvement in the status of the tissue bed supplied or drained by the involved vascular segment. " 06/01/2001 - "Thrombolytic agents are an attractive form of early therapy because they have the ability to eliminate obstructive thrombus in the deep veins and should therefore help provide protection against PTS. The perceived benefits of early and rapid recanalization in preserving valve function has been the basis for the use of lytic therapy to treat acute DVT." 04/01/1988 - "Thrombosis of intravascular catheters is a well-recognized and potentially serious complication, which has been treated successfully with thrombolytic agents. " 05/01/2005 - "Although no trials directly comparing intra-arterial and i.v. delivery of thrombolytics exist, intra-arterial thrombolysis has several potential advantages, including angiographic assessment of the thrombus and the site of occlusion and collateral circulation, improved recanalization, and delivery of higher local concentrations of thrombolytic agents and extending the therapeutic time window for treatment. " 10/01/1993 - "Furthermore, this platelet-rich thrombosis model permits continuous observation of the process of thrombus formation and subsequent thrombolysis and provides a useful tool for the screening and evaluation of efficacy of new antithrombotic agents." Order ALL the reference details at left...
3.	Stroke (Strokes) 08/01/2008 - "Examples such as enhancement of thrombolytic agents by ultrasound have proven to be beneficial for acute stroke patients and peripheral arterial occlusions. " 01/01/2004 - "Recent clinical trials have suggested that other antithrombotic agents may be beneficial in acute ischemic stroke. " 01/01/1999 - "Furthermore, medical therapy with antithrombotic agents will be instituted which, used with good results also in acute cerebral stroke, proved to be effective in the reduction of vascular events in patients with extracranial atherosclerotic plaques. " 01/01/2004 - "Patient compliance with the recommended treatment is of major importance, given the somewhat limited efficacy of antithrombotic agents in stroke prevention. " 10/01/2002 - "Available antiplatelet regimens offer only partial protection against stroke and more efficacious antithrombotic agents would be useful. " Order ALL the reference details at left...
4.	Hemorrhage 04/01/2001 - "Although current thrombolytic agents have proven their clinical benefit, the failure to rapidly reperfuse some patients and the persistent bleeding risk represent areas for improvement in therapy. " 02/01/1987 - "Appropriate dose regimens for thrombolytic agents in specific clinical situations is critical to maximize therapeutic efficacy while minimizing the risk of significant bleeding." 07/01/2008 - "Bleeding complications may be reduced by use of new antithrombotic agents and by improved attention to dosing with current agents. " 01/01/2009 - "METHODS: All randomised controlled trials of anti-fibrinolytic agents given for bleeding during the postpartum period were included in this review. " 05/01/2008 - "BACKGROUND: Studies show that holding single antithrombotic agents perioperatively increases the risk of acute thrombotic events and does not significantly decrease the risk of bleeding complications in dermatological surgery. " Order ALL the reference details at left...
5.	Pulmonary Embolism 10/01/1995 - "BACKGROUND: Thrombolytic agents have been used successfully to treat patients with massive pulmonary embolism and cardiorespiratory insufficiency, but experience with these drugs in pregnancy is limited. " 03/01/1993 - "Thrombolytic agents are widely used as first line treatment in severe acute pulmonary embolisms. " 11/01/2005 - "Efficacy of thrombolytic agents in the treatment of pulmonary embolism." 01/01/2008 - "OBJECTIVE: An unsettled issue is the use of thrombolytic agents in patients with acute pulmonary embolism (PE) who are hemodynamically stable but have right ventricular (RV) enlargement. " 05/01/2003 - "Several other case reports and small series showed successful treatment of pulmonary embolism during similar circumstances using high-dose bolus injection of thrombolytic agents. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Heparin (Liquaemin)
2.	Streptokinase
3.	Tissue Plasminogen Activator (Alteplase)
4.	Warfarin (Coumadin)
5.	Fibrinolytic Agents (Antithrombotic Agents)
6.	Urokinase-Type Plasminogen Activator (Urokinase)
7.	Anticoagulants
8.	Aspirin (Acetylsalicylic Acid)
9.	Thrombin
10.	Plasminogen Activators (Plasminogen Activator)

Related Therapies and Procedures

1.	Thrombolytic Therapy
2.	Angioplasty (Angioplasties)
3.	Microbubbles
4.	Thoracostomy
5.	Subcutaneous Injections

Best Treatments:
Research Summary Report
on Myocardial Infarction

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 2308 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>